A novel platform to produce human monoclonal antibodies: The next generation of therapeutic human monoclonal antibodies discovery

mAbs

Volumn 3, Issue 2, 2011, Pages 203-208

  Duvall, Marcus ^a   Bradley, Norma ^a   Fiorini, Ryan N ^a  

^a Immunologix Inc   (United States)

Author keywords

Antibody; B cell; Human; Monoclonal; Na ve; Novel platform; Therapeutic

Indexed keywords

ALEMTUZUMAB; CETUXIMAB; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; PALIVIZUMAB; ANTIGEN;

ARTICLE; B LYMPHOCYTE; CELL IMMORTALIZATION; DRUG RESEARCH; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE TRANSFORMATION; MONONUCLEAR CELL; SOMATIC HYPERMUTATION; TONSIL; VDJ EXON; BIOSYNTHESIS; BIOTECHNOLOGY; CYTOLOGY; EVALUATION; GENE REARRANGEMENT; IMMUNOLOGY; METHODOLOGY; MUTATION; PALATINE TONSIL; PHYSIOLOGY; VIRUS CELL TRANSFORMATION;

ANTIBODIES, MONOCLONAL; ANTIGENS; B-LYMPHOCYTES; BIOTECHNOLOGY; CELL TRANSFORMATION, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR; MUTATION; PALATINE TONSIL;

EID: 79952714838     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.3.2.14774     Document Type: Article

References (34)

1. Sullivan F. Antibody Technology Developments (Technical Insights) 2005; 30.
2. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009; 157:220-33.
3. Smith SL. Ten years of Orthoclone OKT3 (muromonab-CD3): a review. J Transpl Coord 1996; 6:109-19. (Pubitemid 26386137)
4. Aggarwal S. What's fueling the biotech engine - 2009-2010. Nat Biotech 2010; 28:1165-71.
5. Scolnik PA. mAbs: a business perspective. mAbs 2009; 1:179-84.
6. Neuberger MS, Williams GT, Mitchell EB, Jouhal SS, Flanagan JG, Rabbitts TH. A hapten-specific chimaeric IgE antibody with human physiological effector function. Nature 1985; 314:268-70. (Pubitemid 15076516)
7. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986; 321:522-5. (Pubitemid 16052256)
8. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23:1073-8. (Pubitemid 41486385)
9. Presta LG. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 2006; 58:640-56. (Pubitemid 44262411)
10. Hoet RM, Cohen EH, Kent RB, Rookey K, Schoonbroodt S, Hogan S, et al. Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nat Biotechnol 2005; 23:344-8. (Pubitemid 41094423)
11. Rothe C, Urlinger S, Lohning C, Prassler J, Stark Y, Jager U, et al. The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. J Mol Biol 2008; 376:1182-200.
12. Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD. Isolating and engineering human antibodies using yeast surface display. Nat Protoc 2006; 1:755-68.
13. Lonberg N. Human monoclonal antibodies from transgenic mice. Handb Exp Pharmacol 2008; 69-97.
14. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9:767-74.
15. Crowe JE Jr. Recent advances in the study of human antibody responses to influenza virus using optimized human hybridoma approaches. Vaccine 2009; 27:47-51.
16. Shannon-Lowe C, Baldwin G, Feederle R, Bell A, Rickinson A, Delecluse HJ. Epstein-Barr virus-induced B-cell transformation: quantitating events from virus binding to cell outgrowth. J Gen Virol 2005; 86:3009-19.
17. Aman P, Ehlin-Henriksson B, Klein G. Epstein-Barr virus susceptibility of normal human B lymphocyte populations. J Exp Med 1984; 159:208-20. (Pubitemid 14182827)
18. Miller G, Lipman M. Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci USA 1973; 70:190-4.
19. Kanbe E, Zhang DE. A simple and quick method to concentrate MSCV retrovirus. Blood Cells Mol Dis 2004; 33:64-7. (Pubitemid 38829600)
20. O'Doherty U, Swiggard WJ, Malim MH. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol 2000; 74:10074-80.
21. Ferrari S, Mudde GC, Rieger M, Veyradier A, Kremer Hovinga JA, Scheiflinger F. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2009; 7:1703-10.
22. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies. mAbs 2010; 2:256-65.
23. Richards J, Auger J, Peace D, Gale D, Michel J, Koons A, et al. Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4. Cancer Res 1999; 59:2096-101. (Pubitemid 29217671)
24. Kipriyanov SM, Little M. Generation of recombinant antibodies. Mol Biotechnol 1999; 12:173-201. (Pubitemid 29531808)
25. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984; 81:6851-5. (Pubitemid 15221019)
26. Chadd HE, Chamow SM. Therapeutic antibody expression technology. Curr Opin Biotechnol 2001; 12:188-94. (Pubitemid 32247407)
27. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332:323-7. (Pubitemid 18091075)
28. Tempest PR, Bremner P, Lambert M, Taylor G, Furze JM, Carr FJ, et al. Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. Biotechnology (NY) 1991; 9:266-71.
29. Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25:5616-23.
30. Collarini EJ, Lee FE, Foord O, Park M, Sperinde G, Wu H, et al. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. J Immunol 2009; 183:6338-45.
31. Sutkowski N, Rubinchik S. Human monoclonal antibodies and methods for producing the same. PCT/ US2008/072124. Inventor 2007.
32. Wulff H, Knaus HG, Pennington M, Chandy KG. K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. J Immunol 2004; 173:776-86. (Pubitemid 38924252)
33. Siemer D, Kurth J, Lang S, Lehnerdt G, Stanelle J, Kuppers R. EBV transformation overrides gene expression patterns of B cell differentiation stages. Mol Immunol 2008; 45:3133-41.
34. Sun SQ, Guo HC, Sun DH, Yin SH, Shang YJ, Cai XP, et al. Development and validation of an ELISA using a protein encoded by ORF2 antigenic domain of porcine circovirus type 2. Virol J 2010; 7:274.